Neil Solomons, MB BS

Consultant
Drug Farm

Disclosure information not submitted.

Presentation(s):

• Preliminary immunologic and clinical Phase 1b study outcomes from patients with ROSAH syndrome treated with the first-in-class ALPK1 inhibitor DF-003

  Friday, April 17, 2026
  12:45 PM - 1:00 PM US ET